Salarius Pharmaceuticals (SLRX) Earnings Date, Estimates & Call Transcripts

$0.51
+0.01 (+2.01%)
(As of 04/24/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 9Estimated
Actual EPS
(Mar. 22)
-$0.22 Beat By $0.79
Consensus EPS
(Mar. 22)
-$1.01
Skip Charts & View Estimated and Actual Earnings Data

SLRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SLRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Salarius Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($6.70)($6.70)($6.70)
Q2 20241($6.70)($6.70)($6.70)
Q3 20241($6.70)($6.70)($6.70)
Q4 20241($6.71)($6.71)($6.71)
FY 20244($26.81)($26.81)($26.81)
Q1 20251($5.85)($5.85)($5.85)
Q2 20251($5.85)($5.85)($5.85)
Q3 20251($5.89)($5.89)($5.89)
Q4 20251($5.89)($5.89)($5.89)
FY 20254($23.48)($23.48)($23.48)

SLRX Earnings Date and Information

Salarius Pharmaceuticals last released its quarterly earnings data on March 22nd, 2024. The reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $0.79. Salarius Pharmaceuticals has generated ($4.53) earnings per share over the last year (($4.53) diluted earnings per share). Earnings for Salarius Pharmaceuticals are expected to grow in the coming year, from ($26.80) to ($23.50) per share. Salarius Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.

Salarius Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/9/2024
Estimated)
------- 
3/22/2024Q4 2023($1.01)($0.22)+$0.79($0.22)--
11/9/2023Q3 2023($1.07)($0.65)+$0.42($0.65)--
8/10/2023Q2 2023($1.26)($1.43)($0.17)($1.43)--
5/11/2023Q1 2023($1.98)($2.23)($0.25)($2.23)--
3/27/2023Q4 2022($2.16)($2.83)($0.67)($2.83)--
11/10/2022Q3 2022($2.85)($2.47)+$0.38$1.47--
8/8/2022Q2 2022($2.75)($2.25)+$0.50($0.09)--    
5/12/2022Q1 2022-($3.25)($3.25)($0.13)--
3/10/2022Q4 2021($2.50)($2.25)+$0.25($0.09)--    
11/4/2021Q3 2021($2.25)($2.00)+$0.25($0.08)--    
8/5/2021Q2 2021($1.50)($1.75)($0.25)($0.07)$1.10 million$0.57 million  
5/12/2021Q1 2021($3.00)($1.50)+$1.50($0.06)-$1.27 million  

Salarius Pharmaceuticals Earnings - Frequently Asked Questions

When is Salarius Pharmaceuticals's earnings date?

Salarius Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on SLRX's earnings history.

Did Salarius Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Salarius Pharmaceuticals (NASDAQ:SLRX) reported ($0.22) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.01) by $0.79. Learn more on analysts' earnings estimate vs. SLRX's actual earnings.

How much revenue does Salarius Pharmaceuticals generate each year?

Salarius Pharmaceuticals (NASDAQ:SLRX) has a recorded annual revenue of $1.84 million.

How much profit does Salarius Pharmaceuticals generate each year?

Salarius Pharmaceuticals (NASDAQ:SLRX) has a recorded net income of -$12.54 million. SLRX has generated -$4.53 earnings per share over the last four quarters.

What is Salarius Pharmaceuticals's EPS forecast for next year?

Salarius Pharmaceuticals's earnings are expected to grow from ($26.80) per share to ($23.50) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:SLRX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners